Kyoko Soejima
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
clinical electrophysiology
Open Date: 2017-04-01
Close Date: 2018-03-01
Articles (4)
Background The relationship between oral anticoagulant (OAC) status after catheter ablation (CA) for atrial fibrillation (AF) and the risks of ischemic stroke or major bleeding events is still unknown. Methods This is a subanalysis of the RYOUMA registry, a prospective multicenter observational study of Japanese patients who underwent CA for AF in 2017–2018. Results Of the 2844 patients, the rate of DOAC continuation was 48.1%, 69.6%, and 80.9% in patients with a CHADS2 score of 0–1, 2, and 3–6, respectively. Among the patients taking DOACs with a CHADS2 score of 0–1 and 2, the incidence rates of major bleeding were significantly higher than those of ischemic stroke or systemic embolic events (SEEs) (1.3%/year [95% CI, 0.6–2.1] vs. 0.3%/year [95% CI, 0.0–0.7], p = 0.019; 1.8%/year [95% CI, 0.6–3.0] vs. 0.2%/year [95% CI, 0.0–0.6], p = 0.018, respectively). However, there was no difference between the incidence rates of major bleeding events and ischemic stroke or SEEs in patients taking DOACs with a CHADS2 score of 3–6 (1.6%/year [95% CI, 0.2–3.0] vs. 1.0%/year [95% CI, 0.0–2.1], p = 0.474). Conclusions In patients with a CHADS2 score of 2, those who continued taking DOACs had a higher incidence rate of major bleeding events compared to ischemic stroke/SEEs, similar to those with a CHADS2 score of 0–1. Conversely, in patients with a CHADS2 score of 3–6, the incidence rates of both ischemic stroke/SEEs and major bleeding were similarly high. Trial Registration: The study was registered as UMIN000026092 (University Hospital Medical Information Network‐Clinical Trial Registry)
Year:
2025
Background The efficacy of balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary disease (CTEPD) with or mild pulmonary hypertension (PH) or without PH remains unknown. Exercise pulmonary hypertension (Ex-PH) is associated with impaired exercise capacity and ventilatory efficiency, even under normalized pulmonary hemodynamics at rest. We hypothesized that patients with Ex-PH and/or hypoxemia would be candidates for BPA. We aimed to verify the prevalence and clinical profiles of Ex-PH and the effect of BPA on oxygenation and Ex-PH in patients with CTEPD with mean pulmonary arterial pressure (mPAP) 3.0, and non-Ex-PH. Results Overall, six patients had mild PH (mPAP: 21–24 mmHg), and 16 and 13 were assigned to the Ex-PH and Non-Ex-PH groups, respectively. There were no significant differences in the clinical parameters, including hemodynamics at rest, blood gas analysis, and 6-minute walk distance, between the Ex-PH and Non-Ex-PH groups. Among the 16 patients with Ex-PH and/or long-term oxygen therapy (LTOT), BPA improved the World Health Organization-functional class (WHO-FC) and PaO 2 in association with a decrease in the mPAP/CO slope. All nine patients discontinued LTOT after BPA. No significant complications were observed during each BPA session. Conclusions Ex-PH was common among patients with CTEPD and mPAP < 25 mmHg. BPA can improve symptoms, oxygenation, and exercise hemodynamics in patients with CTEPD and Ex-PH and/or hypoxemia. What is Known? BPA has been recommended for patients with non-operable CTEPH. Although there is still a small body of evidence, BPA for patients with CTEPD with mild PH (mPAP < 25 mmHg) or without PH can safely improve symptoms. The prevalence of Ex-PH in CTEPD patients with or without PH is unknown. What the Study Adds? Approximately 50% of CTEPD patients with mild PH or without PH had Ex-PH. In patients with CTEPD with mPAP < 25 mmHg, BPA improves exercising hemodynamics, such as the mPAP/CO slope, which could be a parameter to determine the indication for BPA. Graphical Abstract. The distribution of exercise pulmonary hypertension (Ex-PH) in patients with chronic thromboembolic pulmonary disease (CTEPD) with mild pulmonary hypertension (PH) or without PH, and efficacy of balloon pulmonary angioplasty (BPA) for CTEPD with Ex-PH and/or hypoxemia. Blue person symbols mean Ex-PH, and white person symbols mean non-Ex-PH.
Year:
2024
Background We aimed to quantify the incidence of atrial fibrillation (AF) in patients with cryptogenic stroke globally, as well as separately in patients in and outside of Japan, using an implantable loop recorder from a prospective, observational, Reveal LINQ Registry. Methods and Results Patients developing cryptogenic stroke and monitored by implantable loop recorder for searching AF were studied. The primary end point was incidence of AF within 36 months after insertion. Secondary end points were recurrent ischemic stroke/transient ischemic attack and AF‐related treatment strategies. A total of 271 patients (61.6±14.3 years, 170 men, 60 from Japan) were enrolled from 12 countries. AF was detected in 28.2% at 36 months. The median time from enrollment to AF detection was 7.9 months. During the first 12 months, the AF detection rate slope was relatively steeper in the Japanese subgroup versus non‐Japanese patients. However, by 3 years, the cumulative incidence of AF detection did not differ between groups. Age was the only variable associated with AF detection (hazard ratio, 1.05 [95% CI, 1.02–1.07] per year), trending higher in older age groups. Of the 271 patients, 11 (4.1%) developed recurrent ischemic stroke/transient ischemic attack; AF was detected by implantable loop recorder in only 1 of these patients. Patients with detected AF were more commonly taking oral anticoagulation than those without AF at the last follow‐up (64.7% versus 25.3%, P <0.001). Conclusions The rate of AF detection was similar to other studies in stroke populations monitored by implantable loop recorders, including CRYSTAL‐AF (Cryptogenic Stroke and Underlying Atrial Fibrillation), STROKE‐AF (Stroke of Unknown Cause and Underlying Atrial Fibrillation) and PER‐DIEM (Post‐Embolic Rhythm Detection With Implantable Versus External Monitoring). Patients with detected AF more commonly initiated anticoagulation than those without AF.
Year:
2024
Background The symptom for identification of pulmonary arterial hypertension (PAH) is dyspnea on exertion, with a concomitant decrease in exercise capacity. Even patients with hemodynamically improved PAH may have impaired exercise tolerance; however, the effect of central and peripheral factors on exercise tolerance remains unclear. We explored the factors contributing to exercise capacity and ventilatory efficiency in patients with hemodynamically normalized PAH after medical treatment. Methods and Results In total, 82 patients with PAH (age: median 46 [interquartile range, 39–51] years; male:female, 23:59) and mean pulmonary arterial pressure ≤30 mm Hg at rest were enrolled. The exercise capacity, indicated by the 6‐minute walk distance and peak oxygen consumption, and the ventilatory efficiency, indicated by the minute ventilation versus carbon dioxide output slope, were assessed using cardiopulmonary exercise testing with a right heart catheter. The mean pulmonary arterial pressure was 21 (17–25) mm Hg, and the 6‐minute walk distance was 530 (458–565) m, whereas the peak oxygen consumption was 18.8 (14.8–21.6) mLꞏmin −1 ꞏkg −1 . The multivariate model that best predicted 6‐minute walk distance included peak arterial mixed venous oxygen content difference (β=0.46, P <0.001), whereas the best peak oxygen consumption predictors included peak cardiac output (β=0.72, P <0.001), peak arterial mixed venous oxygen content difference (β=0.56, P <0.001), and resting mean pulmonary arterial pressure (β=−0.25, P =0.026). The parameter that best predicted minute ventilation versus carbon dioxide output slope was the resting mean pulmonary arterial pressure (β=0.35, P =0.041). Quadriceps muscle strength was moderately correlated with exercise capacity (6‐minute walk distance; ρ=0.57, P <0.001; peak oxygen consumption: ρ=0.56, P <0.001) and weakly correlated with ventilatory efficiency (ρ = −0.32, P =0.007). Conclusions Central and peripheral factors are closely related to impaired exercise tolerance in patients with hemodynamically normalized PAH.
Year:
2023
Collaborators (12)
Andrea Natale
Docenti di ruolo di Ia fascia
University of Rome Tor Vergata
Toru Satoh
-
Ritsushi Kato
-
Teruyuki Hirano
Professor and Chairman
Kyorin University
Hirofumi Tomita
-
Akihiko Nogami
Professor
University of Tsukuba
Takumi Inami
Senior Lecturer
Kyorin University
Hiroshi Morita
Professor
-
Shingen Owada
Iwate Medical University
Scott Kasner
Professor, Clinician-Educator
University of Pennsylvania
Alpesh N Amin
University of California, Irvine
Teiichi Yamane
-
Make your next move.
Prepare your application
Review drafts before you send them.